Muaiad Kittaneh, MD, MBA, FACP
Dr. Muaiad Kittaneh is a medical oncologist and associate professor at the Loyola University of Chicago where he focuses on patients diagnosed with breast cancer, melanoma, and gastrointestinal cancers, including peritoneal mesothelioma. He is one of the few peritoneal mesothelioma specialists in the region and has played a significant role in the creation of the mesothelioma program at Loyola alongside Dr. Wickii Vigneswaran.[1]
To that end, Dr. Kittaneh helped develop a team of surgeons, oncologists, pathologists, radiologists, and radiation oncologists who all specialize in treatment of the rare, asbestos-related disease. The multidisciplinary group established a specialized mesothelioma tumor board that meets regularly to review each case and discuss diagnostic and treatment options to provide patients with the best outcomes.[1]
Education and Career
Dr. Kittaneh attended medical school at the Al-Quds University Medical School in the Palestinian Authority. He completed an internship and residency in Internal Medicine at the University of Illinois at Chicago and was named chief resident at Advocate Christ Medical Center. He completed a fellowship in Hematology/Oncology at the University of Miami Hospital and Clinics. He also earned an MBA in Healthcare Management from the Quinlan School of Business at Loyola University Chicago.
After completing his medical education and training, Dr. Kittaneh accepted a position as an Assistant Professor at the Karmanos Cancer Institute and Wayne State University where he focused on clinical trials, experimental therapeutics, and oncology drug development before moving on to an Associate Professor position at Loyola University of Chicago.[1]
Research
In addition to treating patients with peritoneal mesothelioma, Dr. Kittaneh has served as a Principal Investigator and Co-investigator on many phase I-III clinical trials at Karmanos Cancer Institute/WSU and Loyola University Chicago. He has conducted clinical trials and research in the field of experimental therapy, determining dosages of newly discovered or invented drugs.[1]
His most recent publications include:[2]
Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. Kittaneh, M; Berkelhammer, C JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Werner, TL; Sachdev, J; Swisher, EM; Gutierrez, M; Kittaneh, M; Stein, MN; Xiong, H; Dunbar, M; Sullivan, D; Komarnitsky, P; more…
Cancer medicine (2018)
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Abraham, J; Coleman, R; Elias, A; Holmes, FA; Kalinsky, K; Kittaneh, M; Lower, E; Mahtani, R; Terry Mamounas, E; Pegram, M; more…
Breast cancer research and treatment (2018)
